GLP-1 medications linked to reduced physical activity in first large wearable study

• In the ENDO 2026 study, daily steps fell from 5,047 to 4,487 on average after starting a GLP-1, and moderate-to-vigorous physical activity dropped from 28 to 22 minutes per day
• This is conference-presented research from ENDO 2026 — it has not yet been published in a peer-reviewed journal
• The study is observational — it cannot tell us whether GLP-1 therapy caused the decline, or whether other factors explain it
• Physical activity matters during GLP-1 treatment because it helps preserve lean muscle mass while fat is lost

Researchers led by Maharjan analyzed Fitbit wearable data from a cohort of GLP-1 users before and after treatment initiation. The key findings, as reported by the Endocrine Society:

• Daily step counts fell from 5,047 (±3,073) to 4,487 (±3,133) — a decrease of approximately 560 steps per day (p<0.001)
• Moderate-to-vigorous physical activity (MVPA) fell from 28 to 22 minutes per day
• The pattern was observed across multiple GLP-1 receptor agonists, not just one drug

The change in step count, while modest in absolute terms, was statistically significant. The researchers noted the pattern held even as participants were losing weight — which is counterintuitive, since weight loss is often associated with increased mobility.

GLP-1 medications produce weight loss that includes both fat mass and lean mass. How much lean muscle mass is preserved during treatment depends in part on whether people maintain adequate protein intake and engage in resistance exercise.

Reduced physical activity during a period of rapid weight loss is clinically relevant because:

• Muscle mass requires mechanical stimulus (movement, resistance) to be maintained
• Lower activity levels may compound lean mass losses beyond what the medication alone produces
• Cardiometabolic fitness benefits — separate from weight loss — depend on regular physical activity

This doesn't mean GLP-1 users should worry unduly. But it does suggest that physical activity planning may deserve explicit attention in a GLP-1 treatment conversation.

The study cannot determine why activity fell. Several explanations are plausible, and they are not mutually exclusive:

• Caloric restriction effects: GLP-1 drugs suppress appetite significantly. Eating less means fewer calories available for activity; fatigue and reduced energy are common early side effects of caloric restriction
• Nausea and gastrointestinal side effects: Common early in treatment, nausea may reduce motivation or ability to exercise during the dose escalation period
• Behavioral changes: People who believe the medication is "doing the work" may unconsciously reduce their activity — this is a documented pattern in weight loss research generally
• Selection effects in the data: Wearable data has inherent biases; people who feel unwell may also wear their devices less consistently

None of these explanations have been confirmed or ruled out by this research.

Before drawing clinical conclusions from this study, these limitations matter:

This is conference-presented research. As of July 2026, the full paper has not been published in a peer-reviewed journal. The findings have not undergone peer review. Conference abstracts can sometimes differ from published results.

The study is observational. Wearable data analysis cannot establish causation. The observed activity decline happened during GLP-1 therapy, but many other factors changed at the same time — diet, calorie intake, nausea, support structures, behavior. We cannot attribute the decline to GLP-1 medication based on this data alone.

The study design details matter. The sample size, follow-up duration, and whether the decline was sustained or resolved over time have not been publicly confirmed in a peer-reviewed source.

• Whether the activity decline is temporary (concentrated in the early dose-escalation phase) or sustained throughout treatment
• Whether it is larger with some GLP-1 agents than others
• Whether structured exercise counseling at treatment initiation changes the pattern
• What the long-term clinical impact is on lean mass, cardiometabolic fitness, and weight maintenance

A peer-reviewed publication will be needed to assess the full methodology and conclusions.

• Should we build a structured physical activity plan into my GLP-1 treatment from the start — not just as an optional add-on?
• If I'm experiencing nausea or fatigue early in treatment, are there strategies for maintaining activity while managing side effects?
• Would resistance training be appropriate for my situation during weight loss, and how do I fit it in?

• Daily step count or active minutes on your wearable device — flag significant declines to your care team
• Whether fatigue or nausea are limiting your activity, and when in the dose cycle it occurs
• Lean muscle indicators: grip strength, ability to perform daily physical tasks
• Body composition if your care team orders it (DEXA or equivalent)

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Endocrine Society ENDO 2026 press release — Maharjan et al.
• ScienceDaily coverage of ENDO 2026 study
• ENDO 2026 abstract — Losing pounds, not gaining steps